Satellos Bioscience Inc.
TSX:MSCL.TOBiotechnology
+$0.01 today
- Market cap
- $182.89M
- Beta
- 1.17
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.32
Volume 0.01M
Average 0.02M
MSCL.TO Deferred Tax Liabilities
Taxes owed in future periods because of timing differences between accounting and tax rules.
Satellos Bioscience Inc.TSX: MSCL.TO
Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026
Deferred tax liabilities remains negative
Q1 FY2026 deferred tax liabilities was $0, compared with $0 a year earlier.
Context
- Deferred tax liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Deferred tax liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Tax Liabilities history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Tax Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Tax Liabilities vs competitors
How MSCL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred tax liabilities is compared through growth and share of total assets rather than absolute size.
- Deferred tax liabilities amounts to 0.0% of total assets for MSCL.TO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Apr 2026 | CA$0 CAD | — | — | 0.0% | |
| Apr 2026 | CA$0 CAD | — | — | 0.0% | |
| Peer median (excluding MSCL.TO) | — | — | — | 0.0% | |
Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · CAD | FY2024 Dec 2024 · CAD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.87M | 1.92M | 22.07M | 57.66M | 9.79M |
| Short-term Investments | 0 | 0 | 17.52M | 12.2M | 17.87M |
| Net Receivables | 527.98K | 260.44K | 583K | 626K | 369.33K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.57K | 4K | 0 | (6.92K) |
| Total Current Assets | 5.44M | 2.23M | 40.32M | 73.01M | 31.83M |
| Property, Plant & Equipment (Net) | 8.19K | 9K | 19K | 5K | 4.99K |
| Goodwill | 0 | (190) | 0 | 0 | 0 |
| Intangible Assets | 7.14M | 3.92M | 3.92M | 0 | 0 |
| Long-term Investments | 0 | 42K | 41K | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 7.14M | 3.97M | 3.98M | 5K | 4.99K |
| Total Assets | 12.59M | 6.2M | 44.3M | 73.02M | 31.83M |
| Account Payables | 1.13M | 1.47M | 1.04M | 2.97M | 1.77M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | (7.47K) |
| Total Current Liabilities | 2.1M | 2.83M | 3.62M | 5.16M | 4.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.1M | 2.83M | 3.62M | 5.16M | 4.1M |
| Common Stock | 28.32M | 30.21M | 61.92M | 105.73M | 85.67M |
| Retained Earnings | (20.29M) | (31.61M) | (47.5M) | (75.6M) | (81.82M) |
| Accumulated OCI | (1.44K) | 1.09M | 21.24M | (217K) | 13.73M |
| Other Stockholders Equity | 0 | 0 | 0 | 27.62M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 10.48M | 3.37M | 40.67M | 67.86M | 27.73M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (4.87M) | (1.92M) | (22.07M) | (57.66M) | (9.79M) |
Satellos Bioscience Inc.
TSX:MSCL.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.